AnteoTech Limited (ADO.AX)
AUD 0.01
(0.0%)
AUD 0.01
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 | -11.57 Million AUD | 22.11% |
| 2023 | -14.85 Million AUD | -1.91% |
| 2022 | -12.07 Million AUD | -66.07% |
| 2021 | -7.18 Million AUD | -98.53% |
| 2020 | -3.67 Million AUD | -17.79% |
| 2019 | -3.23 Million AUD | -23.62% |
| 2018 | -2.52 Million AUD | -38.13% |
| 2017 | -1.82 Million AUD | 60.04% |
| 2016 | -4.57 Million AUD | 24.82% |
| 2015 | -5.03 Million AUD | -137.36% |
| 2014 | -2.56 Million AUD | -24.78% |
| 2013 | -2.22 Million AUD | 9.31% |
| 2012 | -3.06 Million AUD | -6.04% |
| 2011 | -2.73 Million AUD | 0.09% |
| 2010 | -2.18 Million AUD | -15.81% |
| 2009 | -1.84 Million AUD | -14.79% |
| 2008 | -1.6 Million AUD | -53.47% |
| 2007 | -1.04 Million AUD | 54.0% |
| 2006 | -5.62 Million AUD | -48.59% |
| 2005 | -1.37 Million AUD | 42.41% |
| 2004 | -2.89 Million AUD | 16.7% |
| 2003 | -2.77 Million AUD | 22.47% |
| 2002 | -9.16 Million AUD | -195.91% |
| 2001 | -1.39 Million AUD | -27.43% |
| 2000 | -1.09 Million AUD | -26906.87% |
| 1999 | 4078.00 AUD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q4 | -6.35 Million AUD | 0.0% |
| 2024 FY | - AUD | 5.42% |
| 2024 Q2 | -5.64 Million AUD | 0.0% |
| 2023 Q2 | -6.37 Million AUD | 0.0% |
| 2023 FY | - AUD | -1.91% |
| 2023 Q4 | -5.98 Million AUD | 0.0% |
| 2022 FY | - AUD | -66.07% |
| 2022 Q4 | -6.6 Million AUD | 0.0% |
| 2022 Q2 | -5.51 Million AUD | 0.0% |
| 2021 FY | - AUD | -98.53% |
| 2021 Q2 | -2.56 Million AUD | 0.0% |
| 2021 Q4 | -4.73 Million AUD | 0.0% |
| 2020 Q4 | -1.79 Million AUD | 0.0% |
| 2020 FY | - AUD | -17.79% |
| 2020 Q2 | -1.87 Million AUD | 0.0% |
| 2019 FY | - AUD | -23.62% |
| 2019 Q2 | -1.52 Million AUD | 0.0% |
| 2019 Q4 | -1.6 Million AUD | 0.0% |
| 2018 Q4 | - AUD | 0.0% |
| 2018 Q2 | -2.16 Million AUD | 0.0% |
| 2018 FY | - AUD | -38.13% |
| 2017 Q4 | - AUD | 0.0% |
| 2017 FY | - AUD | 60.04% |
| 2017 Q2 | -144.59 Thousand AUD | 0.0% |
| 2016 Q4 | - AUD | 0.0% |
| 2016 Q2 | -4.42 Million AUD | 0.0% |
| 2016 FY | - AUD | 24.82% |
| 2015 FY | - AUD | -137.36% |
| 2015 Q4 | -3.81 Million AUD | 0.0% |
| 2015 Q2 | -2.27 Million AUD | 0.0% |
| 2014 Q2 | -622.23 Thousand AUD | 0.0% |
| 2014 Q4 | -1.94 Million AUD | 0.0% |
| 2014 FY | - AUD | -24.78% |
| 2013 Q2 | -773.05 Thousand AUD | -30.02% |
| 2013 Q1 | -594.57 Thousand AUD | 0.0% |
| 2013 FY | - AUD | 9.31% |
| 2013 Q4 | -1.44 Million AUD | -166.01% |
| 2013 Q3 | -544.78 Thousand AUD | 29.53% |
| 2012 Q4 | - AUD | 100.0% |
| 2012 Q2 | -594.57 Thousand AUD | -7.01% |
| 2012 Q1 | -555.61 Thousand AUD | 0.0% |
| 2012 FY | - AUD | -6.04% |
| 2012 Q3 | -594.57 Thousand AUD | 0.0% |
| 2011 Q3 | -555.61 Thousand AUD | 0.0% |
| 2011 FY | - AUD | 0.09% |
| 2011 Q2 | -555.61 Thousand AUD | 1.46% |
| 2011 Q1 | -563.82 Thousand AUD | 0.0% |
| 2011 Q4 | - AUD | 100.0% |
| 2010 Q2 | -563.82 Thousand AUD | -15.71% |
| 2010 Q3 | -563.82 Thousand AUD | 0.0% |
| 2010 FY | - AUD | -15.81% |
| 2010 Q4 | - AUD | 100.0% |
| 2010 Q1 | -487.26 Thousand AUD | 0.0% |
| 2009 Q2 | -487.26 Thousand AUD | -10.86% |
| 2009 Q3 | -487.26 Thousand AUD | 0.0% |
| 2009 Q4 | - AUD | 100.0% |
| 2009 Q1 | -439.54 Thousand AUD | 0.0% |
| 2009 FY | - AUD | -14.79% |
| 2008 Q3 | -439.54 Thousand AUD | 0.0% |
| 2008 Q1 | -315.72 Thousand AUD | 0.0% |
| 2008 FY | - AUD | -53.47% |
| 2008 Q4 | - AUD | 100.0% |
| 2008 Q2 | -439.54 Thousand AUD | -39.22% |
| 2007 FY | - AUD | 54.0% |
| 2007 Q4 | - AUD | 100.0% |
| 2007 Q2 | -315.72 Thousand AUD | 78.96% |
| 2007 Q1 | -1.5 Million AUD | 0.0% |
| 2007 Q3 | -315.72 Thousand AUD | 0.0% |
| 2006 FY | - AUD | -48.59% |
| 2006 Q2 | -1.5 Million AUD | -80.95% |
| 2006 Q3 | -1.5 Million AUD | 0.0% |
| 2006 Q1 | -829.28 Thousand AUD | 0.0% |
| 2006 Q4 | - AUD | 100.0% |
| 2005 Q3 | -829.28 Thousand AUD | 0.0% |
| 2005 Q1 | -768.82 Thousand AUD | 0.0% |
| 2005 Q4 | - AUD | 100.0% |
| 2005 Q2 | -829.28 Thousand AUD | -7.86% |
| 2005 FY | - AUD | 42.41% |
| 2004 Q3 | -768.82 Thousand AUD | 0.0% |
| 2004 Q4 | - AUD | 100.0% |
| 2004 FY | - AUD | 16.7% |
| 2004 Q1 | -1.54 Million AUD | 0.0% |
| 2004 Q2 | -768.82 Thousand AUD | 50.11% |
| 2003 Q4 | - AUD | 100.0% |
| 2003 Q1 | -4.13 Million AUD | 0.0% |
| 2003 Q3 | -1.54 Million AUD | 0.0% |
| 2003 Q2 | -1.54 Million AUD | 62.74% |
| 2003 FY | - AUD | 22.47% |
| 2002 Q1 | -698.57 Thousand AUD | 0.0% |
| 2002 Q2 | -4.13 Million AUD | -492.11% |
| 2002 FY | - AUD | -195.91% |
| 2002 Q3 | -4.13 Million AUD | 0.0% |
| 2002 Q4 | - AUD | 100.0% |
| 2001 Q2 | -698.57 Thousand AUD | -155.61% |
| 2001 FY | - AUD | -27.43% |
| 2001 Q4 | - AUD | 100.0% |
| 2001 Q3 | -698.57 Thousand AUD | 0.0% |
| 2001 Q1 | -273.29 Thousand AUD | 0.0% |
| 2000 Q1 | 1019.50 AUD | 0.0% |
| 2000 Q2 | -273.29 Thousand AUD | -26906.87% |
| 2000 Q3 | -273.29 Thousand AUD | 0.0% |
| 2000 Q4 | -273.29 Thousand AUD | 0.0% |
| 2000 FY | - AUD | -26906.87% |
| 1999 Q3 | 1019.50 AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1999 Q4 | 1019.50 AUD | 0.0% |
| 1999 Q2 | 1019.50 AUD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AdAlta Limited | -5.3 Million AUD | -118.209% |
| Acrux Limited | -7.93 Million AUD | -45.895% |
| Amplia Therapeutics Limited | -4.55 Million AUD | -153.772% |
| Biome Australia Limited | -1.57 Million AUD | -633.151% |
| BTC Health Limited | 1.05 Million AUD | 1196.476% |
| Chimeric Therapeutics Limited | -11.29 Million AUD | -2.4% |
| CSL Limited | 4.73 Billion AUD | 100.244% |
| Clarity Pharmaceuticals Ltd | -44.64 Million AUD | 74.084% |
| Clinuvel Pharmaceuticals Limited | 51.86 Million AUD | 122.311% |
| Noxopharm Limited | -5.94 Million AUD | -94.618% |
| PharmAust Limited | -9.45 Million AUD | -22.422% |
| Proteomics International Laboratories Limited | -7.88 Million AUD | -46.703% |
| Prescient Therapeutics Limited | -7.18 Million AUD | -61.028% |
| PYC Therapeutics Limited | -38.11 Million AUD | 69.644% |
| Race Oncology Limited | -14.2 Million AUD | 18.534% |
| Starpharma Holdings Limited | -12.57 Million AUD | 7.999% |
| EZZ Life Science Holdings Limited | 10.37 Million AUD | 211.522% |
| Botanix Pharmaceuticals Limited | -13.91 Million AUD | 16.871% |
| Memphasys Limited | -3.3 Million AUD | -249.817% |
| Nyrada Inc. | -4.59 Million AUD | -151.751% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | -694.347% |
| Telix Pharmaceuticals Limited | 22.96 Million AUD | 150.383% |
| Bio-Gene Technology Limited | -2.97 Million AUD | -288.942% |
| Zelira Therapeutics Limited | -36.44 Million AUD | 68.248% |
| Patrys Limited | -3.49 Million AUD | -231.342% |
| Dimerix Limited | -24.95 Million AUD | 53.639% |
| Neuren Pharmaceuticals Limited | 199.26 Million AUD | 105.807% |
| Orthocell Limited | -11.68 Million AUD | 0.943% |
| Imugene Limited | -147.97 Million AUD | 92.181% |
| Cynata Therapeutics Limited | -9.95 Million AUD | -16.289% |
| Immutep Limited | -42.87 Million AUD | 73.012% |
| Arovella Therapeutics Limited | -8.83 Million AUD | -30.995% |
| Alterity Therapeutics Limited | -19.57 Million AUD | 40.879% |
| Nanollose Limited | -1.14 Million AUD | -908.011% |
| Invex Therapeutics Ltd | -720.44 Thousand AUD | -1506.095% |
| NeuroScientific Biopharmaceuticals Limited | -1.79 Million AUD | -544.161% |
| Island Pharmaceuticals Limited | -2.81 Million AUD | -310.592% |
| Biotron Limited | -5.04 Million AUD | -129.58% |
| Radiopharm Theranostics Limited | -45.37 Million AUD | 74.5% |
| Tissue Repair Ltd | -5.77 Million AUD | -100.363% |
| Hexima Limited | -995.54 Thousand AUD | -1062.277% |
| Paradigm Biopharmaceuticals Limited | -64.53 Million AUD | 82.071% |
| Recce Pharmaceuticals Ltd | -21.35 Million AUD | 45.814% |
| Avecho Biotechnology Limited | -3.24 Million AUD | -256.852% |
| Actinogen Medical Limited | -12.92 Million AUD | 10.45% |
| Immuron Limited | -6.19 Million AUD | -86.859% |
| Argenica Therapeutics Limited | -1.89 Million AUD | -509.771% |